Nicotinamide mononucleotide supplementation improves polycystic ovary syndrome by activating silent regulatory protein 2 mediated lactate dehydrogenase A lysine 119 deacetylation to enhance glycolytic activity.

Zhang Z, Xue H, Tu H, Lei X, Huang K, Yang X, Xie Q, Guo Z, Zhang S, Huo P

International journal of biological macromolecules17 Oct 2026

PMID42892420DOI10.1016/j.ijbiomac.2026.154894PepBankPUB-42892420

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In PCOS rats, NMN reversed insulin resistance versus vehicle.
In plain wordsIn rats with PCOS, NMN reduced insulin resistance versus vehicle.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
DecreaseInsulin resistance
Study
ratn: not reported in source
Letrozole and high-fat-diet PCOS
Comparator
Vehicle
Outcome group
Glycemic control · Metabolic and weight
Studied dose
500 mg/kg/d · 30 daysAs given in this study (rat).
Source sentences
Summary
NMN supplementation significantly reversed insulin resistance, hyperandrogenism, estrous cycle disorder, and polycystic ovarian morphology in PCOS rats, and simultaneously increased ovarian NAD⁺ levels and glycolytic activity.
1 context sentence(design, population, supporting numbers)
Summary · context
We established a PCOS rat model via letrozole (1 mg/kg/d) gavage combined with high-fat diet for 30 days; after successful modeling, rats were randomly assigned to receive either vehicle or NMN (500 mg/kg/d) for an additional 30 days
Report a problemFND-4289242001
02AnimalAnimal study (in vivo)Efficacy outcome
In PCOS rats, NMN reversed hyperandrogenism versus vehicle.
In plain wordsIn rats with PCOS, NMN reduced excess androgen levels versus vehicle.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
DecreaseHyperandrogenism
Study
ratn: not reported in source
Letrozole and high-fat-diet PCOS
Comparator
Vehicle
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
500 mg/kg/d · 30 daysAs given in this study (rat).
Source sentences
Summary
NMN supplementation significantly reversed insulin resistance, hyperandrogenism, estrous cycle disorder, and polycystic ovarian morphology in PCOS rats, and simultaneously increased ovarian NAD⁺ levels and glycolytic activity.
1 context sentence(design, population, supporting numbers)
Summary · context
We established a PCOS rat model via letrozole (1 mg/kg/d) gavage combined with high-fat diet for 30 days; after successful modeling, rats were randomly assigned to receive either vehicle or NMN (500 mg/kg/d) for an additional 30 days
Report a problemFND-4289242002
03AnimalAnimal study (in vivo)Efficacy outcome
In PCOS rats, NMN reversed estrous cycle disorder versus vehicle.
In plain wordsIn rats with PCOS, NMN reduced reproductive cycle disorder versus vehicle.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
DecreaseEstrous cycle disorder
Study
ratn: not reported in source
Letrozole and high-fat-diet PCOS
Comparator
Vehicle
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
500 mg/kg/d · 30 daysAs given in this study (rat).
Source sentences
Summary
NMN supplementation significantly reversed insulin resistance, hyperandrogenism, estrous cycle disorder, and polycystic ovarian morphology in PCOS rats, and simultaneously increased ovarian NAD⁺ levels and glycolytic activity.
1 context sentence(design, population, supporting numbers)
Summary · context
We established a PCOS rat model via letrozole (1 mg/kg/d) gavage combined with high-fat diet for 30 days; after successful modeling, rats were randomly assigned to receive either vehicle or NMN (500 mg/kg/d) for an additional 30 days
Report a problemFND-4289242003
04AnimalAnimal study (in vivo)Efficacy outcome
In PCOS rats, NMN reversed polycystic ovarian morphology versus vehicle.
In plain wordsIn rats with PCOS, NMN reduced polycystic ovarian changes versus vehicle.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
DecreasePolycystic ovarian morphology
Study
ratn: not reported in source
Letrozole and high-fat-diet PCOS
Comparator
Vehicle
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
500 mg/kg/d · 30 daysAs given in this study (rat).
Source sentences
Summary
NMN supplementation significantly reversed insulin resistance, hyperandrogenism, estrous cycle disorder, and polycystic ovarian morphology in PCOS rats, and simultaneously increased ovarian NAD⁺ levels and glycolytic activity.
1 context sentence(design, population, supporting numbers)
Summary · context
We established a PCOS rat model via letrozole (1 mg/kg/d) gavage combined with high-fat diet for 30 days; after successful modeling, rats were randomly assigned to receive either vehicle or NMN (500 mg/kg/d) for an additional 30 days
Report a problemFND-4289242004
05AnimalAnimal study (in vivo)Efficacy outcome
In PCOS rats, NMN increased ovarian NAD+ levels versus vehicle.
In plain wordsIn rats with PCOS, NMN increased ovarian NAD+ levels versus vehicle.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
IncreaseOvarian NAD+
Study
ratn: not reported in source
Letrozole and high-fat-diet PCOS
Comparator
Vehicle
Outcome group
Receptor activity and mechanism · Reproductive and sexual health
Studied dose
500 mg/kg/d · 30 daysAs given in this study (rat).
Source sentences
Summary
NMN supplementation significantly reversed insulin resistance, hyperandrogenism, estrous cycle disorder, and polycystic ovarian morphology in PCOS rats, and simultaneously increased ovarian NAD⁺ levels and glycolytic activity.
1 context sentence(design, population, supporting numbers)
Summary · context
We established a PCOS rat model via letrozole (1 mg/kg/d) gavage combined with high-fat diet for 30 days; after successful modeling, rats were randomly assigned to receive either vehicle or NMN (500 mg/kg/d) for an additional 30 days
Report a problemFND-4289242005
06AnimalAnimal study (in vivo)Efficacy outcome
In PCOS rats, NMN increased ovarian glycolytic activity versus vehicle.
In plain wordsIn rats with PCOS, NMN increased ovarian glucose breakdown versus vehicle.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
IncreaseOvarian glycolytic activity
Study
ratn: not reported in source
Letrozole and high-fat-diet PCOS
Comparator
Vehicle
Outcome group
Receptor activity and mechanism · Reproductive and sexual health
Studied dose
500 mg/kg/d · 30 daysAs given in this study (rat).
Source sentences
Summary
NMN supplementation significantly reversed insulin resistance, hyperandrogenism, estrous cycle disorder, and polycystic ovarian morphology in PCOS rats, and simultaneously increased ovarian NAD⁺ levels and glycolytic activity.
1 context sentence(design, population, supporting numbers)
Summary · context
We established a PCOS rat model via letrozole (1 mg/kg/d) gavage combined with high-fat diet for 30 days; after successful modeling, rats were randomly assigned to receive either vehicle or NMN (500 mg/kg/d) for an additional 30 days
Report a problemFND-4289242006
07LabIn vitro (cells)Mechanism
In granulosa cells, NMN promoted SIRT2-mediated LDHA deacetylation at K119.
In plain wordsIn cells, NMN promoted SIRT2-mediated removal of acetyl groups from LDHA at K119.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
IncreaseLDHA K119 deacetylation
Study
humann: not reported in source
Testosterone-treated KGN cells
Outcome group
Receptor activity and mechanism · Reproductive and sexual health
Studied dose
Dose not stated
Source sentences
Summary
Mechanistically, NMN promoted SIRT2-mediated deacetylation of LDHA at K119, which enhanced glycolytic activity, promoted proliferation, and inhibited apoptosis in ovarian GCs.
1 context sentence(design, population, supporting numbers)
Summary · context
The underlying molecular mechanism was verified in testosterone (10 μM)-treated human granulosa-like KGN cells via a series of molecular assays including qRT-PCR, western blotting, co-immunoprecipitation (Co-IP), and site-directed mutagenesis.
Report a problemFND-4289242007
08LabIn vitro (cells)Efficacy outcome
In granulosa cells, NMN enhanced glycolytic activity through SIRT2-mediated LDHA deacetylation.
In plain wordsIn cells, NMN increased glucose breakdown through SIRT2-mediated LDHA deacetylation.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
IncreaseGlycolytic activity
Study
humann: not reported in source
Testosterone-treated KGN cells
Outcome group
Receptor activity and mechanism · Reproductive and sexual health
Studied dose
Dose not stated
Source sentences
Summary
Mechanistically, NMN promoted SIRT2-mediated deacetylation of LDHA at K119, which enhanced glycolytic activity, promoted proliferation, and inhibited apoptosis in ovarian GCs.
1 context sentence(design, population, supporting numbers)
Summary · context
The underlying molecular mechanism was verified in testosterone (10 μM)-treated human granulosa-like KGN cells via a series of molecular assays including qRT-PCR, western blotting, co-immunoprecipitation (Co-IP), and site-directed mutagenesis.
Report a problemFND-4289242008
09LabIn vitro (cells)Efficacy outcome
In granulosa cells, NMN promoted proliferation.
In plain wordsIn cells, NMN increased granulosa cell multiplication.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
IncreaseGranulosa cell proliferation
Study
humann: not reported in source
Testosterone-treated KGN cells
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated
Source sentences
Summary
Mechanistically, NMN promoted SIRT2-mediated deacetylation of LDHA at K119, which enhanced glycolytic activity, promoted proliferation, and inhibited apoptosis in ovarian GCs.
1 context sentence(design, population, supporting numbers)
Summary · context
The underlying molecular mechanism was verified in testosterone (10 μM)-treated human granulosa-like KGN cells via a series of molecular assays including qRT-PCR, western blotting, co-immunoprecipitation (Co-IP), and site-directed mutagenesis.
Report a problemFND-4289242009
10LabIn vitro (cells)Efficacy outcome
In granulosa cells, NMN inhibited apoptosis.
In plain wordsIn cells, NMN reduced programmed death of granulosa cells.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
DecreaseGranulosa cell apoptosis
Study
humann: not reported in source
Testosterone-treated KGN cells
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated
Source sentences
Summary
Mechanistically, NMN promoted SIRT2-mediated deacetylation of LDHA at K119, which enhanced glycolytic activity, promoted proliferation, and inhibited apoptosis in ovarian GCs.
1 context sentence(design, population, supporting numbers)
Summary · context
The underlying molecular mechanism was verified in testosterone (10 μM)-treated human granulosa-like KGN cells via a series of molecular assays including qRT-PCR, western blotting, co-immunoprecipitation (Co-IP), and site-directed mutagenesis.
Report a problemFND-4289242010

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
21 Oct 2026, 15:58 UTC
Study results updated
Version 1
21 Oct 2026, 12:50 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.